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Abstract: We kindly thank Drs. Reidler and Kunz for their insightful comments regarding our article.1
The main objective was to study blood oxygen level–dependent cerebrovascular reactivity (BOLD-CVR)
for crossed cerebellar diaschisis (CCD) detection. In this regard, worse clinical outcome in the CCD(+)
group should indeed be interpreted with caution. Ideally, this association needs to be further investigated
in a uniform stroke cohort with sequential follow-up studies. We deliberately did not comment on
supratentorial stroke volume because it is an inexact measurement and does not say anything about
the infarct location.2 Besides, the concept that stroke volume is highly associated with the presence of
CCD in the acute phase remains debatable, as the studies mentioned in the readers’ comment appeared
to be in disagreement.3,4 Nevertheless, we agree that stroke location would be a better variable for
an adjusted analysis. The statement made by Drs. Reidler and Kunz about “inferior cerebrovascular
response indicating more severe supratentorial lesions” is, however, erroneous. We have only shown the
presence of more impaired supratentorial BOLD-CVR in the CCD(+) group. This finding has led us to
believe that hemodynamic alterations may also cause CCD rather than a functional disruption alone. In
general, BOLD imaging enables investigations on resting-state functional connectivity and the influence
of CCD-induced altered metabolism in patients with stroke.5
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Disputes & Debates: Editors’ Choice
Steven Galetta, MD, FAAN, Section Editor
Reader response: BOLD cerebrovascular reactivity as a novelmarker
for crossed cerebellar diaschisis
Paul Reidler (Munich) and Wolfgang G. Kunz (Munich)
Neurology® 2019;93:181–182. doi:10.1212/WNL.0000000000007840
We read with great interest the article by Sebo¨k et al.1 on the detection of crossed cerebellar
diaschisis (CCD) in subacute and chronic stroke using blood oxygen level-dependent (BOLD)-
MRI. They observed that patients with signs of CCD had poorer neurologic function at baseline
and at 3 months. However, because adjusted analysis is lacking, it remains unclear whether CCD
was the cause or consequence of poor outcomes.
The phenomenon of CCD, especially in the acute phase, is highly associated with large-
volume supratentorial stroke.2,3 Acute CCD had no independent impact on outcome and may
be an epiphenomenon of large-volume strokes.2 Correlations of chronic CCD with worse
outcome have been reported, yet adjustments were not made for confounders.4,5 In the current
study, inferior cerebrovascular response indicated more severe supratentorial lesions in the
CCD+ group, yet lesion volumes were not speciﬁed.1 Because lesion volume and distribution
aﬀect outcome, group comparisons should be interpreted with caution concerning a CCD-
outcome relationship. The ﬁnal infarct size and location would provide additional insight on this
matter.
Editors’ note: BOLD cerebrovascular reactivity as a novel marker for
crossed cerebellar diaschisis
In the article “BOLD cerebrovascular reactivity as a novel marker for crossed cerebellar
diaschisis,” Sebo¨k et al. reported similar sensitivity of blood oxygen level–dependent
cerebrovascular reactivity (BOLD-CVR) in detecting crossed cerebellar diaschisis (CCD)
as compared to (15O)-H2O-PET in 25 participants with symptomatic unilateral cere-
brovascular steno-occlusive disease and reported that those with CCD had poorer baseline
neurologic performance and 3-month neurologic outcome. In response, Reidler et al.
question whether CCDwas the cause of consequence of poor outcomes, noting that it may
be an epiphenomenon of large-volume supratentorial strokes and citing conﬂicting evi-
dence in the literature about independent association of CCD with post-stroke outcomes.
They suggest accounting for lesion volume and distribution in the analyses. In their reply,
Niftrik et al. agree that their ﬁnding of worse outcome in those with CCD should be
cautiously interpreted and investigated in follow-up studies, but argue that supratentorial
stroke volume is an inexact measurement, although stroke location would be helpful to
examine. They clarify their ﬁnding of impaired supratentorial BOLD-CVR in the group
with CCD and opine that hemodynamic changes may cause CCD rather than just func-
tional disruption.
Aravind Ganesh, MD, and Steven Galetta, MD
Neurology® 2019;93:181. doi:10.1212/WNL.0000000000007842
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Of interest, CCD has been linked to BOLD signal change, a measure of neuronal metab-
olism and activity. This is encouraging for future studies relating resting-state functional
connectivity and CCD status.
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We kindly thank Drs. Reidler and Kunz for their insightful comments regarding our article.1
The main objective was to study blood oxygen level–dependent cerebrovascular reactivity
(BOLD-CVR) for crossed cerebellar diaschisis (CCD) detection. In this regard, worse clinical
outcome in the CCD(+) group should indeed be interpreted with caution. Ideally, this asso-
ciation needs to be further investigated in a uniform stroke cohort with sequential follow-up
studies.
We deliberately did not comment on supratentorial stroke volume because it is an inexact
measurement and does not say anything about the infarct location.2 Besides, the concept that
stroke volume is highly associated with the presence of CCD in the acute phase remains
debatable, as the studies mentioned in the readers’ comment appeared to be in
disagreement.3,4 Nevertheless, we agree that stroke location would be a better variable for an
adjusted analysis.
The statement made by Drs. Reidler and Kunz about “inferior cerebrovascular response
indicating more severe supratentorial lesions” is, however, erroneous. We have only shown
the presence of more impaired supratentorial BOLD-CVR in the CCD(+) group. This
ﬁnding has led us to believe that hemodynamic alterations may also cause CCD rather than
a functional disruption alone. In general, BOLD imaging enables investigations on resting-
state functional connectivity and the inﬂuence of CCD-induced altered metabolism in
patients with stroke.5
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Reader response: Pearls & Oy-sters: Pembrolizumab-induced
myasthenia gravis
Nathaniel M. Robbins (Hanover, NH), Tahseen Mozaffar (Irvine, CA), Andrew L. Mammen (Baltimore),
Teerin Liewluck (Rochester, MN), Amanda Guidon (Boston), and Victoria H. Lawson (Hanover, NH)
Neurology® 2019;93:183–184. doi:10.1212/WNL.0000000000007845
We read with interest the Resident & Fellow Pearls & Oy-sters article by Algaeed et al.1 on
immune checkpoint inhibitor (ICI)-associated myasthenia gravis (MG). Antibodies such as
anti–acetylcholine receptor antibodies (AChRAbs) may be less speciﬁc for MG after ICI
therapy.2 Positive antibodies may be a marker for autoimmunity in general rather than MG
speciﬁcally; individuals with thymoma receiving ICI therapy who are AChRAb positive pre-
treatment are more likely to develop myositis, even without evidence of neuromuscular
junction (NMJ) disease.2 Complicating the picture, ICI-associated myositis clinically resembles
MG, having a predilection for the oculobulbar and respiratory musculature, and the 2 con-
ditions can overlap.3,4
We recently admitted a patient with metastatic melanoma who developed concurrent myositis
and myocarditis just 2 weeks after a single nivolumab dose. He was initially diagnosed with MG
due to ptosis, ophthalmoparesis, and bulborespiratory weakness. However, arguing against
NMJ pathology, AChRAbs and muscle-speciﬁc kinase antibodies were negative, repetitive
nerve stimulation (RNS) was repeatedly negative despite severe weakness, and pyridostigmine
was ineﬀective. Other reports of ICI-associatedMG also had normal RNS and single-ﬁber EMG
despite severe weakness.5 Our patient refused biopsy, opting for comfort measures, but similar
patients have pathology-demonstrated inﬂammatory myositis.4 The distinction between
myositis and MG is not trivial because ongoing weakness (despite normalized creatine phos-
phokinase [CPK])may require treatment escalation inMG; inmyositis, ongoing weakness may
reﬂect ﬁbrofatty muscle replacement where recovery can lag behind CPK normalization.
Editors’note: Pearls &Oy-sters: Pembrolizumab-inducedmyasthenia
gravis
In the article “Pearls &Oy-sters: Pembrolizumab-inducedmyasthenia gravis,”Algaeed et al.
presented a 73-year-old man who was diagnosed with myasthenia gravis (MG) after
receiving pembrolizumab for recurrent melanoma and had positive anti–acetylcholine
receptor antibodies (AChRAbs). In response, Robbins et al. note that antibodies like
AChRAbs may be less speciﬁc for MG after immune checkpoint inhibitor (ICI) therapy
and may be a marker for general autoimmunity. They note that AChRAb-positive patients
receiving ICI therapy are more likely to develop myositis and that this can clinically
resembleMG. In this regard, they note that some reports of ICI-associatedMGhad normal
repetitive nerve stimulation and single-ﬁber EMG despite severe weakness. Using an
illustrative case, they note that the distinction between myositis and MG has important
implications for clinical management. In response, Algaeed et al. acknowledge these
observations, but note that their patient had unequivocal fatigable ptosis strongly
supporting (not pathognomonic in the editor’s opinion) the diagnosis of MG. The authors
also argue that further understanding of ICI-related autoimmune pathogenesis is needed
before concluding that AChRAbs can just be a marker of general autoimmunity.
Aravind Ganesh, MD, and Steven Galetta, MD
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Tacrolimus or cyclosporine may be useful in ICI-induced myositis when steroids and IV
immunoglobulin are insuﬃcient, although a formal study is needed. Because immune-mediated
neuromuscular disease after ICI treatment is less rare than the authors implied,3,4 clinicians
must learn to distinguish MG from ICI-induced myositis in these cases—understanding that
antibody positivity does not equal NMJ disease.2
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Mohanad Algaeed (Washington, DC)
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Robbins et al. provide critically important observations regarding the complexity of checkpoint
inhibitor–associated autoimmunity—in particular, overlap of autoimmune diseases, speciﬁcally
myasthenia gravis. In our patient,1 there were unequivocal signs of ptosis with fatigue, which are
pathognomonic for myasthenia gravis. There needs to be much greater understanding of
checkpoint inhibitor autoimmune pathogenesis before making the conclusion that the ace-
tylcholine receptor autoantibodies are a simple marker of autoimmunity, rather than being
evidence of myasthenia gravis. The acetylcholine receptor–binding antibody is among the most
speciﬁc tests for any disease, except with the rare exception of thymoma, as noted by Robbins
et al., and some pregnant women.2 Repetitive stimulation has relatively low sensitivity; although
single-ﬁber examination is better, it can often be negative in patients with myasthenia gravis.3
We can all agree that neurologists must be vigilant in rapid identiﬁcation and treatment of
neuromuscular diseases in the context of checkpoint inhibitor therapies. Even case reports will
be valuable in clarifying the presentation of these diseases.
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